share_log

Sangoma Technologies Analyst Ratings

Benzinga Analyst Ratings ·  Feb 13, 2023 07:53
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
02/13/2023 231.67% Canaccord Genuity $13 → $12 Maintains Buy
09/28/2022 259.3% Canaccord Genuity $21 → $13 Maintains Buy
09/22/2022 William Blair Initiates Coverage On → Outperform
05/26/2022 397.5% Northland Capital Markets → $18 Initiates Coverage On → Outperform

What is the target price for Sangoma Technologies (SANG)?

The latest price target for Sangoma Technologies (NASDAQ: SANG) was reported by Canaccord Genuity on February 13, 2023. The analyst firm set a price target for $12.00 expecting SANG to rise to within 12 months (a possible 231.67% upside). 4 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Sangoma Technologies (SANG)?

The latest analyst rating for Sangoma Technologies (NASDAQ: SANG) was provided by Canaccord Genuity, and Sangoma Technologies maintained their buy rating.

When is the next analyst rating going to be posted or updated for Sangoma Technologies (SANG)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sangoma Technologies, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sangoma Technologies was filed on February 13, 2023 so you should expect the next rating to be made available sometime around February 13, 2024.

Is the Analyst Rating Sangoma Technologies (SANG) correct?

While ratings are subjective and will change, the latest Sangoma Technologies (SANG) rating was a maintained with a price target of $13.00 to $12.00. The current price Sangoma Technologies (SANG) is trading at is $3.62, which is out of the analyst's predicted range.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment